title: Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
abstract: Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated. We present here data from a retrospective analysis on metabolic abnormalities occurring during therapy which show increased creatine kinase, inverse creatine kinase-phosphate correlation, cholesterol and triglyceride values.
authors.forename: Anna
authors.initials: A
authors.lastname: Franceschino
authors.forename: Lucia
authors.initials: L
authors.lastname: Tornaghi
authors.forename: Valerie
authors.initials: V
authors.lastname: Benemacher
authors.forename: Sarit
authors.initials: S
authors.lastname: Assouline
authors.forename: Carlo
authors.initials: C
authors.lastname: Gambacorti-Passerini
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D003402:Creatine Kinase / Q000378:metabolism*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000378:metabolism; D008875:Middle Aged; D010710:Phosphates / Q000378:metabolism*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010710:Phosphates; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D003402:Creatine Kinase